We are live on
!
Find out more
AA
ALPS Advisors Portfolio holdings
AUM
$21.3B
1-Year Est. Return
21.71%
This Fund
S&P 500
This Quarter
Est. Return
+1.29%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$8.89B
AUM Growth
-$1.49B
(-14%)
Cap. Flow
-$1.55B
Cap. Flow
% of AUM
-17.42%
Top 10 Holdings %
Top 10 Hldgs %
47.67%
Holding
1,012
New
106
Increased
478
Reduced
302
Closed
124
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Energy Transfer Partners
ET
|
+$37.3M |
| 2 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$31.1M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$27.8M |
| 4 |
Newmont
NEM
|
+$27.4M |
| 5 |
Cummins
CMI
|
+$24.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$430M |
| 2 |
JPMorgan Chase
JPM
|
+$168M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$132M |
| 4 |
Yum! Brands
YUM
|
+$105M |
| 5 |
Pfizer
PFE
|
+$92.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 59.33% |
| 2 | Technology | 6.01% |
| 3 | Healthcare | 4.63% |
| 4 | Consumer Discretionary | 3.72% |
| 5 | Financials | 3.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RXDX
301
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $1.78M | 0.02% |
+45,064
| New | +$1.41M |
|
302
Enanta Pharmaceuticals
ENTA
$372M
| $1.76M | 0.02% |
23,521
-1,250
| -5% | -$98.1K |
|
303
Immunocore
IMCR
$1.78B
| $1.74M | 0.02% |
50,670
-2,993
| -6% | -$108K |
|
|
304
JPMorgan Chase
JPM
$939B
| $1.73M | 0.02% |
10,940
-1,022,895
| -99% | -$168M |
|
|
MYOV
305
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.68M | 0.02% |
+107,982
| New | +$2.06M |
|
306
Rocket Pharmaceuticals
RCKT
$348M
| $1.63M | 0.02% |
74,577
-3,393
| -4% | -$92.6K |
|
307
Northrop Grumman
NOC
$77B
| $1.62M | 0.02% |
4,194
-1,369
| -25% | -$510K |
|
308
Regenxbio
RGNX
$623M
| $1.62M | 0.02% |
49,491
-2,721
| -5% | -$92.7K |
|
309
Atara Biotherapeutics
ATRA
$71.2M
| $1.61M | 0.02% |
4,093
-62
| -1% | -$26.1K |
|
310
Iron Mountain
IRM
$38.2B
| $1.61M | 0.02% |
30,824
-2,594
| -8% | -$123K |
|
311
Organogenesis Holdings
ORGO
$308M
| $1.61M | 0.02% |
174,336
-8,215
| -5% | -$87.3K |
|
|
AAT
312
American Assets Trust
AAT
$1.49B
| $1.61M | 0.02% |
42,810
+18,184
| +74% | +$683K |
|
|
MRUS
313
DELISTED
Merus
MRUS
| $1.59M | 0.02% |
+50,050
| New | +$1.41M |
|
314
Keros Therapeutics
KROS
$199M
| $1.58M | 0.02% |
27,071
-1,528
| -5% | -$76.2K |
|
315
StepStone Group
STEP
$3.48B
| $1.58M | 0.02% |
38,000
-1,000
| -3% | -$44.2K |
|
316
Crinetics Pharmaceuticals
CRNX
$8.86B
| $1.56M | 0.02% |
54,964
+7,528
| +16% | +$186K |
|
317
Anavex Life Sciences
AVXL
$222M
| $1.52M | 0.02% |
+87,972
| New | +$1.67M |
|
|
KYNB
318
Kyntra Bio
KYNB
$28.5M
| $1.51M | 0.02% |
4,292
-249
| -5% | -$77.5K |
|
319
Hess Midstream
HESM
$5.22B
| $1.5M | 0.02% |
54,199
+29,092
| +116% | +$754K |
|
320
Advanced Micro Devices
AMD
$851B
| $1.5M | 0.02% |
10,396
-13,056
| -56% | -$1.75M |
|
321
McEwen Inc
MUX
$1.03B
| $1.49M | 0.02% |
168,427
-7,389
| -4% | -$76.9K |
|
322
Replimune Group
REPL
$814M
| $1.47M | 0.02% |
54,269
-3,053
| -5% | -$91.3K |
|
323
Zoetis
ZTS
$31.6B
| $1.46M | 0.02% |
5,976
-9,045
| -60% | -$1.98M |
|
324
Coherus Oncology
CHRS
$217M
| $1.42M | 0.02% |
88,859
-4,873
| -5% | -$85.2K |
|
|
BDN
325
Brandywine Realty Trust
BDN
$551M
| $1.37M | 0.02% |
101,762
-4,600
| -4% | -$63.2K |
|
Similar funds
PAG
MMH
IC
DSA
VARA
SC
CB
ALPS Advisors's Q4 2021 Portfolio in Review
As of Q4 2021, ALPS Advisors held 1,012 positions worth $8.89B, down 14% from $10.4B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
ALPS Advisors withdrew a net $1.55B in Q4 2021, closing 124 positions and reducing 302 holdings. Its most notable exit was Berkshire Hathaway Class A, an estimated $430M position sold in full.
By sector, the portfolio is most concentrated in Energy at 59% of assets, up from 51% a quarter earlier, followed by Technology and Healthcare.
Against the trend, ALPS Advisors opened a new position in Bristol-Myers Squibb worth $29.6M.
- ALPS Advisors's largest Q4 2021 buy was Bristol-Myers Squibb: 474,459 shares worth $29.6M.
- ALPS Advisors added most to Energy Transfer Partners in Q4 2021, an estimated $37.3M increase.
- ALPS Advisors's biggest Q4 2021 reduction was JPMorgan Chase, cutting an estimated $168M.
- ALPS Advisors fully exited Berkshire Hathaway Class A in Q4 2021, selling an estimated $430M.
- ALPS Advisors's ten largest holdings make up 48% of its $8.89B portfolio in Q4 2021.
- ALPS Advisors opened 106 new positions and closed 124 in Q4 2021.
- ALPS Advisors's portfolio value fell 14% quarter-over-quarter to $8.89B.
Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.